当前位置: 首页 >> 检索结果
306. Mobilising national and regional assets and non-state actors for pandemic preparedness.
作者: Louisa Sun.;Duncan Selbie.;Ali S Khan.;Salim S Abdool Karim.;Helena Legido-Quigley.;Folasade T Ogunsola.;Gwendolen Eamer.;Malebona Precious Matsoso.;Daniel G Bausch.;Dale Fisher.
来源: Lancet. 2025年405卷10487期1320-1324页 307. Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.
作者: Idnan Yunas.;Md Asiful Islam.;Kulandaipalayam N Sindhu.;Adam J Devall.;Marcelina Podesek.;Sayeda Sadia Alam.;Shoumik Kundu.;Kristie-Marie Mammoliti.;Ashraf Aswat.;Malcolm J Price.;Javier Zamora.;Olufemi T Oladapo.;Ioannis Gallos.;Arri Coomarasamy.
来源: Lancet. 2025年405卷10488期1468-1480页
An understanding of the causes of postpartum haemorrhage is needed to provide appropriate treatment and services. Knowledge of the risk factors for postpartum haemorrhage can help address modifiable risk factors. We did a systematic review and meta-analysis to identify and quantify the various causes and risk factors for postpartum haemorrhage.
309. The promise and compromise of the WHO Pandemic Agreement for spillover prevention and One Health.
作者: Alexandra Finch.;Neil M Vora.;Latiffah Hassan.;Chris Walzer.;Raina K Plowright.;Robyn Alders.;Chyna Yong Suit-B.;John H Amuasi.;Moses Mulumba.;Ted Loch-Temzelides.;Sergio Guerrero-Sanchez.;Lawrence O Gostin.
来源: Lancet. 2025年405卷10492期1800-1802页 311. Pancreatic cancer.
作者: Thomas F Stoop.;Ammar A Javed.;Atsushi Oba.;Bas Groot Koerkamp.;Thomas Seufferlein.;Johanna W Wilmink.;Marc G Besselink.
来源: Lancet. 2025年405卷10485期1182-1202页
Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.
|